ROCURONIUM BROMIDE INJECTION SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

ROCURONIUM BROMIDE

から入手可能:

PFIZER CANADA ULC

ATCコード:

M03AC09

INN（国際名）:

ROCURONIUM BROMIDE

投薬量:

10MG

医薬品形態:

SOLUTION

構図:

ROCURONIUM BROMIDE 10MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

5ML

処方タイプ:

Prescription

治療領域:

NEUROMUSCULAR BLOCKING AGENTS

製品概要:

Active ingredient group (AIG) number: 0126317001; AHFS:

認証ステータス:

APPROVED

承認日:

2018-01-04

製品の特徴

PRODUCT MONOGRAPH
PR
ROCURONIUM BROMIDE INJECTION
10 mg/mL, Solution for Injection, 5 mL vial
Sterile and Preservative Free
Non-depolarizing Skeletal Neuromuscular Blocking Agent
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Submission Control No.: 225871
Date of Revision:
May 31, 2019
_Product Monograph - _
_Pr_
_Rocuronium Bromide Injection _
_Page 2 of 36 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND ADMINISTRATION
..............................................................................12
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................26
SPECIAL HANDLING INSTRUCTIONS
.......................................................................26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................26
PART II: SCIENTIFIC INFORMATION
...............................................................................28
PHARMACEUTICAL INFORMATION
..........................................................................28
CLINICAL TR